Postvaccine Anti-SARS-CoV-2 Spike Protein Antibody Development in Kidney Transplant Recipients

Affiliations

¹ Division of Nephrology, Department of Medicine, Columbia University Medical Center, New York, New York, USA.
² New York- Presbyterian Hospital, New York, New York, USA.
³ Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York, USA.

Syed Ali Husain et al. Kidney Int Rep. 2021 Jun.

. 2021 Jun;6(6):1699-1700.

doi: 10.1016/j.ekir.2021.04.017. Epub 2021 Apr 23.

¹ Division of Nephrology, Department of Medicine, Columbia University Medical Center, New York, New York, USA.
² New York- Presbyterian Hospital, New York, New York, USA.
³ Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York, USA.

No abstract available

References

1. Kates O.S., Haydel B.M., Florman S.S. COVID-19 in solid organ transplant: a multi-center cohort study [e-pub ahead of print]. Clin Infect Dis. - DOI
1. Boyarsky B.J., Werbel W.A., Avery R.K. Immunogenicity of a single dose of SARS-CoV-2 messenger RNA vaccine in solid organ transplant recipients. JAMA. 2021;325:1784–1786. - PMC - PubMed
1. Pereira M.R., Mohan S., Cohen D.J. COVID-19 in solid organ transplant recipients: initial report from the US epicenter. Am J Transplant. 2020;20:1800–1808. - PMC - PubMed
1. U.S. Food and Drug Administration website EUA authorized serology test performance. https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-em... Available at:
1. Walsh E.E., Frenck R.W., Jr., Falsey A.R. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. 2020;383:2439–2450. - PMC - PubMed